NOVATO, Calif., Oct. 3, 2012 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc., a biotechnology company, today announced that Emil D. Kakkis, M.D., Ph.D, the company's CEO, will be presenting at the 11th Annual BIO Investor Forum on October 10, 2012 at 9:00am Pacific Time at the Palace Hotel in San Francisco, CA. The presentation will be held in the Pacific Heights conference room. Dr. Kakkis will also be participating as a panelist on the Therapeutic Workshop, "Raring to Go: The Race to Treat Ultra-Rare Disease", being held from 2:00-2:55pm in the Twin Peaks conference room.
About Ultragenyx
Ultragenyx is a privately held, developmental stage biotechnology company committed to bringing life-enhancing therapeutics for patients with rare and ultra-rare genetic diseases, also known as orphan and ultra-orphan diseases, to market. The company focuses on rare metabolic diseases that affect small numbers of patients, but for which the unmet medical need is high and there are no effective treatments. Ultragenyx intends to build a sustainable pipeline of safe and effective therapies to address these underserved diseases.
The company is led by an experienced management team in rare disease therapeutics. Ultragenyx is striving toward an improved model for successful rare disease drug development, which has the potential to increase efficiency while maintaining appropriate safety and efficacy standards. The company believes that it can deliver significant value to patients by building a high-quality pipeline of rare disease therapeutics and efficiently transforming good science into great medicine.
For more information on Ultragenyx, please visit the company's website at www.ultragenyx.com.